AMENDMENT NO.5 TO THE INVESTMENT AGREEMENTInvestment Agreement • June 17th, 2024 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledJune 17th, 2024 Company IndustryThis AMENDMENT NO.5 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of June 13, 2024 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman Islands (the “Buyer”). The Buyer and the Seller are hereinafter referred to as the “Parties” and each a “Party”.
INVESTMENT AGREEMENTInvestment Agreement • December 12th, 2022 • SAIF Partners IV L.P. • Pharmaceutical preparations • New York
Contract Type FiledDecember 12th, 2022 Company Industry JurisdictionThis INVESTMENT AGREEMENT (this “Agreement”) dated as of November 23, 2022 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman Islands (the “Buyer”). The Buyer and the Seller are hereinafter referred to as the “Parties” and each a “Party”.
AMENDMENT NO.1 TO THE INVESTMENT AGREEMENTInvestment Agreement • March 15th, 2023 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledMarch 15th, 2023 Company IndustryThis AMENDMENT NO.1 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of March 15, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman Islands (the “Buyer”). The Buyer and the Seller are hereinafter referred to as the “Parties” and each a “Party”.
Joint Filing AgreementJoint Filing Agreement • July 25th, 2012 • SAIF Partners IV L.P. • Services-motion picture & video tape distribution
Contract Type FiledJuly 25th, 2012 Company IndustryIn accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the American Depositary Shares representing Ordinary Shares, par value US$0.0005 per share, of Bona Film Group Limited, a Cayman Islands company, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same instrument.
Joint Filing AgreementJoint Filing Agreement • November 15th, 2010 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledNovember 15th, 2010 Company IndustryIn accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares, par value US$0.001, of Sinovac Biotech Ltd., and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same instrument.
Joint Filing AgreementJoint Filing Agreement • June 27th, 2017 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledJune 27th, 2017 Company IndustryThis Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Joint Filing AgreementJoint Filing Agreement • February 2nd, 2016 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledFebruary 2nd, 2016 Company IndustryThis Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
AMENDMENT NO.2 TO THE INVESTMENT AGREEMENTInvestment Agreement • May 25th, 2023 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledMay 25th, 2023 Company IndustryThis AMENDMENT NO.2 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of May 25, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman Islands (the “Buyer”). The Buyer and the Seller are hereinafter referred to as the “Parties” and each a “Party”.
Joint Filing AgreementJoint Filing Agreement • October 28th, 2024 • SAIF Partners IV L.P. • Miscellaneous electrical machinery, equipment & supplies
Contract Type FiledOctober 28th, 2024 Company IndustryIn accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value, of Amprius Technologies, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same instrument.
ContractJoint Filing Agreement • May 31st, 2011 • SAIF Partners IV L.P. • Pharmaceutical preparations
Contract Type FiledMay 31st, 2011 Company IndustryIn accordance with Rule 13d-1(k), promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common shares, par value $0.001 per share, of Sinovac Biotech Ltd., and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.